4basebioLSE:4BB -0.95%61 Gross Margin % is 52.60% as of Dec. 2025, which is 22% below its 10-year median of 67.19. GuruFocus rates LSE:4BB with a GF Score™ of 61/100 and a GF Value™ of £28.26 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 734 Biotechnology companies, 4basebio ranks worse than 53.41% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. 4basebio's Gross Profit for the
six
months ended in Dec. 2025 was £0.27 Mil. 4basebio's Revenue for the
six
months ended in Dec. 2025 was £0.52 Mil. Therefore, 4basebio's Gross Margin % for the quarter that ended in Dec. 2025 was 52.60%.
Warning Sign:
4basebio PLC gross margin has been in long-term decline. The average rate of decline per year is -2.6%.
The historical rank and industry rank for 4basebio's Gross Margin % or its related term are showing as below:
LSE:4BB'
s Gross Margin % Range Over the Past 10 Years
Min: -13.86 Med: 67.19 Max: 89.18
Current: 57.53
During the past 7 years, the highestGross Margin % of 4basebio was 89.18%. The lowest was -13.86%. And the median was 67.19%.
LSE:4BB's Gross Margin % is ranked worse than 53.41% of 734
companies
in the Biotechnology industry
Industry Median: 60.795
vs LSE:4BB: 57.53
4basebio had a gross margin of 52.60% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for 4basebio was -2.60% per year.
4basebio (LSE:4BB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
4basebio had a gross margin of 52.60% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
4basebio Gross Margin % Related Terms
4basebio Gross Margin % Historical Data
* Premium members only.
The historical data trend for 4basebio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:4BB vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, 4basebio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4basebio Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4basebio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where 4basebio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
4basebio (LSE:4BB) has a Gross Margin % of 52.60% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on 4basebio and its competitors. This is 22% below median its historical median of 67.19. According to the industry distribution chart, 4basebio ranks #392 out of 734 companies in the Biotechnology industry, placing it in the top 53.4%.
Is 4basebio's Gross Margin % too high?
4basebio's current Gross Margin % of 52.60% is 22% below median its 10-year median of 67.19. The Biotechnology industry median Gross Margin % is 60.80. 4basebio's value of 52.60% is 13.5% below this industry median. Based on the distribution chart, 4basebio ranks #392 out of 734 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 4basebio has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 4basebio ranks #392 out of 734 companies for Gross Margin %. This places 4basebio in the lower half of its industry. The industry median Gross Margin % is 60.80. 4basebio's value of 52.60% is 13.5% below this benchmark. While the company's 10-year median is 67.19 vs. the industry median of 60.80, 4basebio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4basebio's current Gross Margin % of 52.60% is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on 4basebio and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4basebio's current Gross Margin % is 52.60%, which is 22% below median its own 10-year median of 67.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (LSE:4BB) is currently considered Possible Value Trap. The stock's GF Value™ is £28.26, compared to a current price of £5.20 — trading 81.6% below its estimated fair value. The current Gross Margin % is 52.60%, which is 22% below median its 10-year median of 67.19 and 13.5% below the Biotechnology industry median of 60.80. 4basebio's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For 4basebio (LSE:4BB), the current Gross Margin % is 52.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4basebio (LSE:4BB) Overvalued in 2026?
Based on GuruFocus' analysis, 4basebio stock appears to be undervalued.
The current stock price of £5.20 is trading 81.6% below its estimated GF Value™ of £28.26.
GuruFocus considers 4basebio to be Possible Value Trap.
Key valuation signals for LSE:4BB:
Gross Margin %: 52.60% (22% below median its 10-year median of 67.19)
GF Value™: £28.26 vs. price of £5.20 (81.6% below fair value)
Industry Position: 13.5% below the Biotechnology median (#392 of 734)
No single metric tells the full story. See the LSE:4BB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
61GF Score
Get the complete analysis for LSE:4BB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:4BB has been successfully added to your 
